Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.87 by 78.16 percent. This is a 72.86 percent decrease over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $139.20 million which missed the analyst consensus estimate of $163.12 million by 14.66 percent. This is a 0.15 percent increase over sales of $139.00 million the same period last year.
Taro Pharmaceutical Indus Q3 EPS $0.19 May Not Compare To $0.87 Estimate, Sales $139.20M Miss $163.12M Estimate
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.87 by 78.16 percent. This is a 72.86 percent decrease over earnings of $0.70 per
Related Posts
Twitter Adds To Its Revenue Stream With The Latest Move
Twitter Inc (NYSE:TWTR) is nearing the launch of its Super Follow feature, the company said in its blog. It will…
Apple Patents Folding Smartphone That Can ‘Heal’ Its Own Scratches
Apple Inc (NASDAQ: AAPL) has been granted a patent that mentions “self-healing” technology for devices such as foldable smartphones.
EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients
Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression.
Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London.